Related Experiment Videos
[The best in 2000 on heart failure]
1Service de cardiologie, CHU Nancy-Brabois, Allée du Morvan, 54500 Vandoeuvre-lès-Nancy.
Insights
Advances in cardiac failure management in 2000 included new insights into epidemiology, hypertrophic cardiomyopathy, and dilated cardiomyopathy. Type B natriuretic peptide and beta-blockers showed therapeutic promise.
Area of Science:
- Cardiology
- Pathology
- Genetics
Context:
- Cardiac failure research in 2000 encompassed diverse pathological fields.
- Epidemiological data for cardiac failure in France and Europe were updated.
- Significant advancements were made across various aspects of cardiac failure.
Purpose:
- To review and summarize key advancements in cardiac failure during the year 2000.
- To highlight new findings in epidemiology, diagnostics, and therapeutics for cardiac failure.
- To underscore the evolving understanding of cardiac failure's etiology and management.
Summary:
- The implantable defibrillator's role in preventing sudden death in hypertrophic cardiomyopathy was confirmed.
- The prognostic significance of etiology in dilated cardiomyopathy was established, and acute fulminating viral myocarditis was identified as a distinct entity.
- New genetic abnormalities in dilated cardiomyopathy were discovered, and type B natriuretic peptide emerged as a key biomarker for diagnosis, prognosis, and treatment (nesiritide).
- Beta-blockers were confirmed effective, even in severe cardiac failure.
- Biventricular stimulation offered a new therapeutic option for advanced cardiac failure.
- The first cellular transplantation by a French team marked a significant milestone.
Impact:
- These advancements refined the diagnosis and prognosis of various cardiac failure types.
- Therapeutic strategies were enhanced with confirmed roles for beta-blockers and new options like biventricular stimulation.
- The identification of genetic factors and novel biomarkers like type B natriuretic peptide opens avenues for personalized medicine.
- Pioneering cellular transplantation research offers future hope for cardiac regeneration.
Abstract:
The advances in cardiac failure are permanent. In 2000, once again, they concerned all fields of pathology. Complementary information of the epidemiology of the disease in France and Europe has been published. The prevention of sudden death by the implantable defibrillator in hypertrophic cardiomyopathy has been confirmed. The prognostic role of the aetiology of dilated cardiomyopathy has been demonstrated and the distinct clinical entity of acute fulminating viral myocarditis with an excellent long-term prognosis has been identified. New genetic abnormalities have been found in different forms of dilated cardiomyopathy. One of the most important advances concerns the neurohormones and the rise of interest in type B natriuretic peptide, for diagnosis, prognosis, as well as treatment (nesiritide). From the therapeutic point of view, the importance of betablockers has been confirmed, including in severe cardiac failure. The therapeutic value of biventricular stimulation resynchronising the two ventricles seem to be an additional therapeutic opportunity for patients with advanced cardiac failure. The summit of 2000 remains the first cellular transplantation carried out by a Parisian French team.